Free Newsletter
Fierce Cloud Services for Biopharma R&D
Cloud computing--a data-crunching force multiplier that allows companies to draw on resources across the Internet, either on the fly or as a dedicated service--is potentially disruptive to companies because it changes the dynamic of who owns the capital assets, turning traditional IT infrastructure models on their heads.
Do your homework before selecting a cloud service provider. That's the message from those who know.
"Be cautious, but be open-minded," says Rick Franckowiak, director for systems engineering at the Pharmaceutical Research & Development IT organization of Johnson & Johnson. Likewise: "Be careful," says Brian Boruff, vice president for cloud computing at systems integration consultancy Computer Sciences Corp., a cloud service provider.
Boruff and Franckowiak explained to FierceBiotech IT the need for such caution, as well as characteristics to look for in cloud service offerings: security, agility, cost elements and biopharma suitability. A summary of our interviews with these experts is available here.
The following pages contain descriptions of a representative sampling of cloud service providers and their offerings. Many such services are available now and the list of providers and offerings is growing rapidly. For this report, we've included a mix of generalists and those with pharma-specific offerings. Descriptions are culled from company information.
Representative cloud service providers, in alphabetical order:
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




